1. Medical Device Innovation Consortium. Patient centered benefit-risk project report: a framework for incorporating information on patient preferences regarding benefit and risk into regulatory assessments of new medical technology. 2015. https://mdic.org/wp-content/uploads/2018/05/MDIC_PCBR_Framework_Web.pdf. Accessed 24 Feb 2021.
2. US Food and Drug Administration. 21st Century Cures Act. https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act. Accessed 13 Apr 2021.
3. IMI-PREFER. Innovation medicine initiative: patient preferences in benefit-risk assessments during the drug life cycle. 2016. https://www.imi-prefer.eu/about/. Accessed 24 Feb 2021.
4. European Medicines Agency. EMA regulatory science to 2025: strategic reflection. 2020. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdf. Accessed 17 Nov 2020.
5. Bouvy JC, Cowie L, Lovett R, Morrison D, Livingstone H, Crabb N. Use of patient preference studies in HTA decision making: a NICE perspective. Patient. 2020;13(2):145–9.